GlassScriptPhysician profile
Lucy Yusun Won
NPI 1497172613
$10,280.95
in general payments reported to CMS, 2019-2025
26 companies · $2,436 in 2025
The $2,436 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,145 · 2020: $1,044 · 2021: $1,292 · 2022: $959 · 2023: $388 · 2024: $2,017 · 2025: $2,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,840.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,804.75 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $1,575.30 | 2019-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $1,539.90 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,249.83 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $588.84 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $520.97 | 2019-2022 | |
| Allergan, INC. | $422.28 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $348.63 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $344.42 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $313.77 | 2019-2025 | Rexulti |
| Almatica Pharma LLC | $205.25 | 2025 | Loreev Xr |
| Sunovion Pharmaceuticals INC. | $194.99 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $179.43 | 2019-2024 | Uzedy |
| Axsome Therapeutics, INC. | $159.87 | 2025 | Auvelity |
| Indivior INC. | $143.11 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $138.77 | 2022 | |
| Avanir Pharmaceuticals, INC. | $125.59 | 2019 | |
| Acadia Pharmaceuticals INC | $106.53 | 2023-2024 | Nuplazid |
| Vanda Pharmaceuticals INC. | $99.79 | 2019-2022 | |
| Adlon Therapeutics L.P. | $55.42 | 2020-2021 | |
| Corium, LLC | $49.92 | 2025 | Azstarys |
| Eisai INC. | $35.36 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $26.52 | 2019 | |
| Neuronetics, INC. | $22.79 | 2023 | Neurostar Tms Therapy System |
| Neos Therapeutics, LP | $16.76 | 2025 | Exxua |
| Supernus Pharmaceuticals, INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucy Won listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.